ProKidney Corp.

NASDAQ:PROK

Biotechnology

Healthcare
$1.04 +0.86%

+$0.02 today

Market cap
$349.70M
Beta
1.70
P/E (TTM)
-3.3
EPS (TTM)
-$0.53
52W Low $0.54High $7.13

Volume 1.80M

Average 0.96M

PROK Weighted Avg Shares (Diluted)

Average shares outstanding including dilutive securities, used to calculate diluted EPS.

ProKidney Corp.NASDAQ: PROK

Weighted Avg Shares (Diluted) · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares (diluted) grows, but more slowly than its trailing trend

Q1 FY2026 weighted avg shares (diluted) of 141.93M shares rose 10.0% year over year, behind the +18.2% change in trailing-twelve-month weighted avg shares (diluted). Sequentially, it rose 5.1% from the prior quarter. Over 3 fiscal years it compounded at +29.6% a year.

Context

  • Weighted avg shares (diluted) increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +10.0% toward the trailing-twelve-month pace of +18.2%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
141.93M+5.1% QoQ
Last fiscal yearDec 2025
133.94M+36.8% YoY
LTMMar 2026
135.66M+18.2% YoY
Weighted Avg Shares (Diluted) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+10.0%——
1 year+36.8%——
3-year CAGR+29.6%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares (Diluted) history

Shares · from the income statement

Latest · FY2025
133.94M USD
Year-over-year change
+36.8%
4-year CAGR
+43.2%

Weighted Avg Shares (Diluted) vs competitors

How PROK compares with its peers on the latest reported figures

  • PROK's LTM Mar 2026 weighted avg shares (diluted) of 135.66M shares is the 2nd highest of the 7 companies compared; the peer median is 70.45M shares.
  • Its year-over-year change of +18.2% is the 2nd highest of 6, against a peer median of +6.5%.
  • Over three fiscal years its annual growth of +29.6% compares with a peer median of +13.4%.
PROK Competitors Peer median
Weighted Avg Shares (Diluted) for PROK and competitors
Company Period LTM YoY 3-year CAGR
ARDXArdelyx, Inc.LTM Mar 2026242.83M +1.9%+15.0%
PROKProKidney Corp.LTM Mar 2026135.66M +18.2%+29.6%
UNCYUnicycive Therapeutics, Inc.LTM Mar 2026107.08M +1045.8%+372.5%
TVTXTravere Therapeutics, Inc.LTM Sep 202692.57M +2.0%+11.8%
DMACDiaMedica Therapeutics Inc.LTM Mar 202648.34M +16.1%+21.1%
MAZEMaze Therapeutics, Inc.LTM Mar 202646.63M +6.5%-0.6%
MENSJyong Biotech Ltd. Ordinary SharesLTM Dec 202471.57K —-1.3%
Peer median (excluding PROK) 70.45M+6.5%+13.4%

Competitors are the stored peer set for PROK. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00076K893K
Cost of Revenue00000
Gross Profit00076K893K
Gross Margin———100.0%100.0%
Research & Development46.26M82.07M106.71M127.67M114.12M
Selling, General & Admin8.86M70.94M44.82M56.08M51.78M
Operating Expenses55.11M153.01M151.52M183.75M165.9M
Depreciation & Amortization1.98M3.04M3.85M5.43M6.58M
EBITDA(53.12M)(143.99M)(125.59M)(158.49M)(144.62M)
EBITDA Margin———-208542.1%-16194.7%
Operating Income(55.11M)(153.01M)(151.52M)(183.68M)(165.01M)
Operating Margin———-241678.9%-18477.8%
Interest Income2K5.98M22.08M19.75M13.81M
Interest Expense0215K12K9K4K
Other Income / Expenses2K5.77M22.07M19.74M13.81M
Income Before Tax(55.11M)(147.24M)(129.45M)(163.93M)(151.2M)
Pre-Tax Margin———-215701.3%-16931.5%
Income Tax Expense38K896K6M(598K)414K
Net Income(55.15M)(108.03M)(35.47M)(61.19M)(68.99M)
Net Margin———-80507.9%-7725.2%
EPS (Basic)(1.73)(1.76)(0.57)(0.62)(0.52)
EPS (Diluted)(1.73)(1.76)(0.57)(0.62)(0.52)
Weighted Avg Shares31.89M61.54M61.71M97.92M133.94M
Weighted Avg Shares (Diluted)31.89M61.54M61.71M97.92M133.94M

ProKidney Corp.

NASDAQ:PROK

Intrinsic Alpha fair value

Locked

Current Price

$1.04

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.